Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.
about
Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical TherapyManagement of carcinoma in situ of the bladder: best practice and recent developmentsImproving diagnostic molecular tests to monitor urothelial carcinoma recurrence.Tackling non-muscle invasive bladder cancer in the clinic.
P2860
Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Novel fluorescence in situ hyb ...... als of intravesical therapies.
@ast
Novel fluorescence in situ hyb ...... als of intravesical therapies.
@en
type
label
Novel fluorescence in situ hyb ...... als of intravesical therapies.
@ast
Novel fluorescence in situ hyb ...... als of intravesical therapies.
@en
prefLabel
Novel fluorescence in situ hyb ...... als of intravesical therapies.
@ast
Novel fluorescence in situ hyb ...... als of intravesical therapies.
@en
P2093
P2860
P356
P1433
P1476
Novel fluorescence in situ hyb ...... als of intravesical therapies.
@en
P2093
Ashish M Kamat
Colin P Dinney
Daniel L Willis
Graciela Nogueras-González
H Barton Grossman
Rian J Dickstein
Rooselvelt Anderson
Ruth L Katz
P2860
P304
P356
10.1111/BJU.13186
P577
2015-06-01T00:00:00Z